QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:DAWN

Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis

$16.52
+0.73 (+4.62%)
(As of 04:37 PM ET)
Today's Range
$15.75
$16.89
50-Day Range
$13.56
$17.46
52-Week Range
$9.67
$17.85
Volume
778,235 shs
Average Volume
596,992 shs
Market Capitalization
$1.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.60

Day One Biopharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
147.6% Upside
$40.60 Price Target
Short Interest
Bearish
16.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Day One Biopharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$722,960 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.66) to ($2.12) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

Medical Sector

642nd out of 938 stocks

Pharmaceutical Preparations Industry

298th out of 433 stocks

DAWN stock logo

About Day One Biopharmaceuticals Stock (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

DAWN Stock Price History

DAWN Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Up 3.8%
DAWN Jul 2024 17.500 call
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals Inc
See More Headlines
Receive DAWN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
3/28/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DAWN
Fax
N/A
Employees
155
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.60
High Stock Price Target
$50.00
Low Stock Price Target
$34.00
Potential Upside/Downside
+147.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-188,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.98 per share

Miscellaneous

Free Float
79,695,000
Market Cap
$1.43 billion
Optionable
Optionable
Beta
-1.48
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Jeremy Bender M.B.A. (Age 53)
    Ph.D., CEO, President & Director
    Comp: $900k
  • Dr. Samuel C. Blackman M.D. (Age 55)
    Ph.D., Co-Founder and Head of R&D
    Comp: $651k
  • Mr. Charles N. York II (Age 47)
    COO, CFO & Secretary
    Comp: $715k
  • Dr. Mike Preigh Ph.D.
    Chief of Technology Operations
  • Mr. Adam Dubow (Age 57)
    General Counsel
  • Ms. Jaa Roberson
    Chief People Officer
  • Dr. Davy Chiodin Ph.D.
    Pharm.D., Chief Development Officer
  • Ms. Lauren Merendino M.B.A. (Age 48)
    Chief Commercial Officer
  • Dr. Elly Barry M.D.
    Chief Medical Officer

DAWN Stock Analysis - Frequently Asked Questions

Should I buy or sell Day One Biopharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DAWN shares.
View DAWN analyst ratings
or view top-rated stocks.

What is Day One Biopharmaceuticals' stock price target for 2024?

7 Wall Street research analysts have issued twelve-month price targets for Day One Biopharmaceuticals' shares. Their DAWN share price targets range from $34.00 to $50.00. On average, they anticipate the company's share price to reach $40.60 in the next year. This suggests a possible upside of 147.6% from the stock's current price.
View analysts price targets for DAWN
or view top-rated stocks among Wall Street analysts.

How have DAWN shares performed in 2024?

Day One Biopharmaceuticals' stock was trading at $14.60 on January 1st, 2024. Since then, DAWN stock has increased by 12.3% and is now trading at $16.40.
View the best growth stocks for 2024 here
.

When is Day One Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our DAWN earnings forecast
.

How were Day One Biopharmaceuticals' earnings last quarter?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) announced its earnings results on Monday, February, 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.07.

What ETFs hold Day One Biopharmaceuticals' stock?

ETFs with the largest weight of Day One Biopharmaceuticals (NASDAQ:DAWN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

When did Day One Biopharmaceuticals IPO?

Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Day One Biopharmaceuticals' major shareholders?

Day One Biopharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.48%), Vanguard Group Inc. (5.46%), Franklin Resources Inc. (4.87%), Braidwell LP (4.84%), Price T Rowe Associates Inc. MD (2.66%) and Price T Rowe Associates Inc. MD (2.66%). Insiders that own company stock include Adam Dubow, Ai Day1 Llc, Charles N York II, Jeremy Bender, Julie Papanek Grant, Michael Gladstone, Papanek Julie Grant, Pharmaceutical Co Ltd Takeda, Samuel C Blackman, Venture Fund Xi LP Atlas and Xi LP Canaan.
View institutional ownership trends
.

How do I buy shares of Day One Biopharmaceuticals?

Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DAWN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners